Pfizer is currently forging ahead making partnerships with small UK Biotech companies that are boosting the innovation pipeline and promise to accelerate the pace of new medicine discovery.
Pfizer – Neusentis (Pfizer’s new research unit) held a networking event last week at Granta Park during Cambridge Awards Week called Partnering with Neusentis, an entrepreneurial Pfizer research unit at the forefront of the new pharma R&D model. Influential people from the life sciences and VC communities attended and were said to be pleased with the initiative.
Dr Ruth McKernan who is a senior vice president at Pfizer and chief scientific officer at Neusentis was pleased with the reaction to the initiative. She said told Business Weekly that “the Cambridge hotspot is proving to be fertile territory for the new and highly focused R&D model that Pfizer is pioneering” She also said that half a dozen potential collaborations had been identified in the last week alone in Cambridge and that small businesses in the sector were often a major source of innovation in their own right.
Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates